This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): epratuzumab tetraxetan, LymphoCide Y-90, (90)Y-epratuzumab, IMMU-102, anti-CD22 antibody-Y-90, yttrium Y 90 epratuzumab
BioMedTracker has separate drug profiles for Epratuzumab and Y-90 Epratuzumab. Please also see Epratuzumab.
Epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen on B-cells, including malignant B-cells. The internalizing property of epratuzumab is believed to be well suited for delivering radiation from the potent radioisotope, yttrium-90, selectively and locally to lymphoma cells that express the CD22 antigen.
Y-90 Epratuzumab News
Pink Sheet Amgen seeking developer for epratuzumab
Pink Sheet Amgen closes epratuzumab trial
Additional information available to subscribers only: